Burosumab exhibits a robust, positive association with improved growth outcomes among pediatric patients with X-linked hypophosphatemia (XLH), according to study findings published in the Journal of Clinical Endocrinology & Metabolism. XLH is a rare, ... See more
Orforglipron treatment (6, 12, and 36 mg) shows significant and comparable reductions in body weight across all body mass index (BMI) categories, according to study results presented at the American Association of Clinical Endocrinology (AACE) Annual Meet... See more
Although both tirzepatide and dulaglutide significantly improve health-related quality of life (HRQoL), tirzepatide may confer more significant benefits among people with long-standing type 2 diabetes (T2D) and those with established atherosclerotic cardi... See more
A reduction in body mass index z-score (BMI-z) of at least 0.25 is associated with similar risk reductions for both metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) among children, according to study results published in JAMA ... See more
Higher body mass index (BMI) and waist circumference are consistently associated with worse cognition among both sexes, according to study findings published in the International Journal of Obesity. Obesity is a known risk factor for cognitive decline and... See more
